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Manuscript title 
Diffusion-weighted imaging as a treatment response biomarker evaluating bone 
metastases in prostate cancer: a pilot study. 
 
Manuscript type: Original Research 
 
Advances in knowledge  
1. All six patients who responded to the Poly (ADP-ribose) polymerase (PARP) 
inhibitor olaparib showed a decrease in total diffusion volume (tDV) (median: -
41.1%; minimum [min], maximum [max]: -58.8%, -6.3%), but no decrease was 
observed in any of the 15 non-responders (median: +20.7%; min, max: +0.0%, 
+76.9%); this difference between responders and non-responders was significant 
(p=0.001).  
2. Increases in median apparent diffusion coefficient (mADC) of the total 
diffusion volume (tDV) after 12-weeks of treatment associated with responses to 
olaparib (OR: 1.08, 95% CI 1.00, 1.15, p=0.037). 
3. When analyzing up to five target bone metastases, changes in entire volume of 
the target bone metastases also inversely associated with response (OR: 0.89, 95% CI 
0.80, 0.99, p=0.037).  
 
Implications for patient care 
1. Clinical qualification of whole body diffusion weighted imaging (WB-DWI) as response biomarker in bone metastases would improve assessment of response to treatment in mCRPC, allowing for optimization of patients care, treatment decision and drug development in this common disease. 
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 Summary statement 
Assessment of bone metastases with whole body diffusion-weighted imaging during 
cancer treatment is feasible, with changes in bone metastases volume and median 
apparent diffusion coefficient being indicators of response to treatment in metastatic 
castration resistant prostate cancer in our pilot study.  
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ABBREVIATIONS 
ADC  Apparent Diffusion Coefficient  
mADC median ADC 
ALP  Alkaline Phosphatase 
CI  Confidence Interval 
CT Computed Tomography  
CTC  Circulating Tumor Cell 
CTSU Clinical Trials and Statistical Unit 
DWI  Diffusion Weighted Imaging 
FOV Field Of View  
HR  Hazard Ratio 
IRB  Institutional Research Board 
LDH Lactate Dehydrogenase 
mCRPC  Metastatic Castration Resistant Prostate Carcinoma  
max maximum 
min minimum 
MRI  Magnetic Resonance Imaging 
ρ  Spearman ́s correlation coefficient 
ROI  Region Of Interest 
SD  Standard Deviation 
tDV  total tumor Diffusion Volume 
PARP poly-(ADP)ribose polymerase 
PCWG Prostate Cancer Working Group 
PTTG  Prostate Targeted Therapy Group 
PSA  Prostate Specific Antigen 
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Q1 1st quartile 
Q3 3rd quartile 
WB Whole Body 
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ABSTRACT 
Purpose 
To determine the usefulness of whole body diffusion weighted imaging (WB-DWI) to 
assess response of bone metastases to treatment in patients with metastatic castration 
resistant prostate cancer (mCRPC). 
 
Materials and methods 
A phase II prospective clinical trial of the poly-(ADP)ribose polymerase (PARP) 
inhibitor olaparib in mCRPC included a prospective magnetic resonance imaging 
(MRI) sub-study; our study was approved by Institutional Research Board (IRB), 
written informed consent was obtained. WB-DWI was performed at baseline and after 
12-weeks of olaparib using a 1.5-T MRI. Areas of DWI signal abnormality in keeping 
with bone metastases were delineated to derive total diffusion volume (tDV); five 
target lesions were also evaluated. Associations of changes in volume of bone 
metastases and median apparent diffusion coefficient ADC (mADC) with response to 
treatment were assessed using the Mann-Whitney test and logistic regression; 
correlation with prostate specific antigen (PSA) and circulating tumor cell (CTC) 
count were assessed using Spearman’s correlation (r).  
 
 
Results 
Twenty-one patients were included. All six responders to olaparib showed a decrease 
in tDV, while no decrease was observed in all non-responders; this difference 
between responders and non-responders was significant (p=0.001). Increases in 
mADC associated with increased odds of response (Odds Ratio [OR]:1.08, 95%CI 
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1.00-1.15, p=0.04). We detected a positive association between changes in tDV and 
best percentage change in PSA and CTC (r=0.63, 95% CI 0.27, 0.83and r=0.77, 95% 
CI 0.51, 0.90). When assessing five target lesions, decreases in volume were 
associated with response (OR for volume increase: 0.89, 95%CI 0.80-0.99, p=0.037).  
 
Conclusion 
Our pilot study showed decreases in volume and increases in mADC of bone 
metastases assessed by WB-DWI can potentially be used as indicators of response to 
olaparib in mCRPC.  
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INTRODUCTION 
Prostate cancer is the second most commonly diagnosed cancer among men 
worldwide (1).  Bone metastases are highly prevalent in patients with metastatic 
castration resistant prostate cancer (mCRPC), the late stage of prostate cancer, 
causing substantial disease-related morbidity and mortality in this population. Bone 
metastases occur in up to 84% of patients with mCRPC and frequently represent the 
only site of metastatic disease (2). 
 
Standard imaging techniques, i.e. computed tomography (CT), and technetium-99m 
bone scintigraphy, fail to accurately evaluate the burden of bone metastases and detect 
changes in response to treatment (3). In fact, the widely used Response Evaluation 
Criteria In Solid Tumors (RECIST) 1.1 (4), do not define response in bone 
metastases, considering these as non-measurable disease. The Prostate Cancer 
Working Group 2 criteria (PCWG2) define progression in bone metastases based on 
the appearance of new lesions on bone scintigraphy, but fail to state any criteria for 
response in bone metastases (5). Therefore, tumor responses in patients with bone 
only metastatic disease rely solely on prostate specific antigen (PSA) falls; the latter 
have not been proven to be a surrogate for improved survival (5-7).  There is an 
urgent unmet need to identify, develop, and validate non-invasive response 
biomarkers for bone metastases in prostate cancer. 
 
Diffusion weighted imaging (DWI) is a functional magnetic resonance imaging 
(MRI) technique that studies the motion of water molecules within a tissue. Apparent 
diffusion coefficient (ADC) is an objective measurement of this water diffusion, 
which has been demonstrated to inversely correlate with cellularity in different tumor 
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types including bone marrow malignancies (8-13). Changes in ADC values after 
treatment have been correlated with tumor responses in different tumor types 
including myeloma, ovarian carcinoma, primary peritoneal carcinoma and 
rhabdomyosarcoma (14-16). Additionally, the volume of bone metastases assessed 
with whole body (WB) DWI has prognostic value in patients with mCRPC (17). 
Limited data about the value of DWI in the assessment of response to bone metastases 
in mCRPC is currently available, coming from small series of patients (18-21). In the 
setting of a prospective clinical trial, we aim to determine the usefulness of whole 
body diffusion weighted imaging (WB-DWI) to assess response of bone metastases to 
treatment in patients with metastatic castration resistant prostate cancer (mCRPC).  
 
MATERIAL AND METHODS 
We conducted a phase II trial of the poly-(ADP)ribose polymerase (PARP) inhibitor 
olaparib (Lynparza, AstraZeneca) in mCRPC (TOPARP-A; CRUK/11/029); patients 
were enrolled from July 2012 to September 2014. A prospective MRI sub-study was 
conducted under institutional research board (IRB) approval at The Royal Marsden 
NHS Foundation Trust. Enrolment to this MRI sub-study was optional; written 
informed consent was obtained for MRI scan acquisition. 
 
Study design 
The primary endpoint of the TOPARP-A trial was response rate, with response 
defined as any of the following: a response of soft tissue/visceral disease according to 
Response Evaluation Criteria In Solid Tumors (RECIST) 1.1(4); a confirmed 
reduction in the prostate specific antigen (PSA) level of ≥50%; or a conversion in the 
circulating tumor cell (CTC) count, with a reduction in the number of CTC from 
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≥5/7.5 ml of blood at baseline to <5/7.5 ml of blood during treatment, with a 
confirmatory assessment at least 4 weeks later (22). Detailed information of the 
inclusion and exclusion criteria and the results of the TOPARP-A trial have been 
published showing a response rate to olaparib in mCRPC of 33% (95% confidence 
interval [CI], 20 to 48%) (23). 
 
Participation in the optional MRI sub-study was offered to those patients without 
contraindication for MRI at The Royal Marsden NHS Foundation Trust. WB-MRI 
was performed at baseline (within 28-days prior to starting treatment) and at Cycle 4 
Day 1 (corresponding to 12-weeks after starting treatment) and every 12-weeks 
subsequently. The primary endpoint of the MRI sub-study was to assess the 
association between changes in parameters derived from WB-DWI (volume of bone 
metastases and median ADC) and response to olaparib. For MRI sub-study purposes, 
patients were classified as responders if they met the definition of the primary 
endpoint of the TOPARP-A trial and if they had not experienced radiological 
progression by 12-weeks. 
 
Patient population in the MRI sub-study 
Patients were included in this study if: a) signed informed consent for the MRI sub-
study in the setting of the TOPARP-A trial, b) bone metastases identified based on 
review of combined imaging modalities: MRI, CT and BS (in all the cases), c) a 
minimum of two paired WB-MRI studies performed at baseline and after 12-weeks of 
treatment. Patients with suboptimal quality WB-MRI or incomplete studies were 
considered un-evaluable for analysis and excluded from the study.  
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Clinical data collection 
Data were collated into an anonymized database and analyzed by the Institute of 
Cancer Research Clinical Trials and Statistical Unit (ICR-CTSU; London, UK). PSA 
and CTC counts were collected at baseline and every 12-weeks while on treatment. 
CTC counts were also pursued at weeks 1, 2, 4 and 8. RECIST assessments were 
evaluated at baseline and every 12-weeks using CT.  
 
Whole-body MRI parameters 
WB-MRI was performed on a 1.5-T MRI scanner (Avanto Siemens Healthcare, 
Erlangen, Germany), using surface and body coils on patients positioned supine. 
Axial images were acquired using free breathing single-shot twice-refocused echo-
planar DWI from the upper cervical spine to mid-thighs, sequentially across four 
imaging stations, each consisting of 50 slices respectively. In addition to WB-DWI, 
anatomical imaging was also acquired using breath-hold axial T1-weighted. The scan 
parameters are summarized in Appendix Table 1. 
  
Imaging analysis 
Images were processed and analyzed with open-access imaging assistant software 
(OsiriX v5.6). Evaluation of T1-weighted and DWI (b50, b900 and ADC maps) was 
performed in order to assess the presence of metastatic bone disease. Regions of 
interest (ROIs) including areas of signal abnormality on DWI b900, corresponding to 
high signal on DWI b900 and low signal on T1-weighted imaging, in keeping with 
metastatic bone disease were delineated. Different delineation techniques of the signal 
abnormality on DWI b900 corresponding to bone metastases were undertaken. Firstly, 
ROI analyses were performed including all areas of signal abnormality on DWI b900 
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and T1-weighted MRI corresponding to bone metastases observed in the axial 
skeleton (spine and pelvis, not including ribs) between C4 and mid-thighs, labeled as 
total diffusion volume (tDV). Secondly, a more limited analysis was performed using 
a RECIST approach of a maximum 5 target representative bone metastases chosen 
using the following criteria: maximum axial dimension >1cm, well-defined lesion 
border and representing different skeletal areas. For this analysis, ROIs including total 
volume of up to 5 target lesions and ROIs including the central slice of the same 
target lesions were chosen. 
Additionally, a single radiologist (RPL) manually delineated the entire axial skeleton 
(spine and pelvis, not including ribs) enclosing normal and abnormal bone marrow 
from C4 to lesser trochanters. This delineation technique was included in view of its 
possible advantage for automated segmentation of the skeleton.  
A semi-automated segmentation tool from the OsiriX software v.5.6 was used for 
delineating ROIs. All the delineation techniques in every WB-DWI were performed 
by a single radiologist  (RPL) with 3 years of experience in WB-DWI; manual 
correction of the segmentation mask corresponding to the regions of interest (ROI) 
was performed by the radiologist where necessary (Figure 1). The volume of 
metastases was calculated as the number of voxels for all ROIs multiplied by the 
voxel volume in each case. The ADC value of every pixel was recorded and 
histogram representations of the ADC values of bone metastases for each patient were 
generated using Microsoft Excel 2010.  
 
 
Statistical analysis 
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Distribution of PSA, CTC counts, median ADC (mADC), tDV, volume and diameter 
of the target lesions at baseline and percentage change after 12-weeks on treatment 
are presented using descriptive statistics. Baseline distributions and median changes 
during treatment in mADC, tDV, volume and diameter of the target lesions are 
compared between responders and non-responders using non-parametric Mann-
Whitney tests and their association with response to treatment using univariate and 
multivariate (adjusting for known prognostic factors of baseline PSA, lactate 
dehydrogenase [LDH] and alkaline phosphatase [ALP]) logistic regression models. 
The correlation between baseline and changes in tDV after 12-weeks on treatment 
with baseline and best percentage change in PSA and CTC respectively were assessed 
using Spearman´s correlation coefficient (r), with 0.4≤|r|<0.6 indicating moderate 
correlation, 0.6≤|r|<0.8 strong correlation and |r|≥0.8 very strong correlation. A 
significance level of 0.05 and 95% CI have been used. No adjustment for reporting of 
multiple analyses has been performed; therefore significant results must be interpreted 
with caution. The analyses are based on a data snapshot taken on 24th April 2015 and 
were performed with Stata version 13 (StataCorp). 
 
RESULTS 
Thirty-two of the 42 patients (76.2%; 32/42) enrolled in the TOPARP-A trial at The 
Royal Marsden NHS Foundation Trust consented to the MRI sub-study.  Six patients 
did not have baseline WB-MRI due to logistic or technical issues. All 26 patients with 
WB-MRI at baseline had bone metastases. Of the 26 patients with baseline WB-MRI, 
5 patients did not have WB-MRI at 12-weeks due to poor performance status. None of 
the cases were excluded due to sub-optimal quality of the WB-MRI or incomplete 
studies. Therefore, 21 patients had evaluable WB-MRI at baseline and after 12-weeks 
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of treatment (Figure 2); all men, median age 68.2 years (minimum [min], maximum 
[max]: 40.8, 79.3 years). The population characteristics at baseline are summarized in 
Table 1. The baseline CT examinations were also reviewed using previously 
described terminology (24); 19 of the 21 patients had sclerotic bone metastases 
whereas 2 patients had mixed osteoblastic/osteolytic disease with predominantly lytic 
metastases. The other sites of metastatic disease outside the bone observed were in 
lymph nodes (57.1%; 12/21), liver (28.6%; 6/21) and lung (23.8%; 5/21). Seven 
patients had bone metastases only at baseline (33.3%;7/21). Six patients (29%;6/21) 
were considered responders to olaparib as per the primary endpoint definition and had 
not progressed prior to 12-weeks. 
 
The median time between the baseline WB-MRI and starting treatment was 6-days 
(1st quartile [Q1], 3rd quartile [Q3]: 2.5, 11 days). The absolute value of the tDV, sum 
of the 5 target lesions total volumes and of the central slice diameters and the mADC 
at baseline assessed by the different delineation techniques is summarized by response 
status in Table 2. The percentage change of these parameters after 12-weeks of 
treatment is summarized by response status in Table 3 and represented in box-plots in 
Appendix  figure 1. 
 
Analysis of axial skeleton DWI b900 signal abnormality 
When delineating all the areas of DWI signal abnormality in keeping with bone 
metastases in the axial skeleton, the median tDV in this population was 0.45 L (min, 
max: 0.01, 1.31 L) and mADC was 782 x10-6 mm2/s (min, max: 684, 1121 x10-6 
mm2/s). These parameters grouped by responders and non-responders are summarized 
in Table 2; there were no statistically significant differences between the baseline 
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distribution of tDV and mADC between the two groups (p=0.243 and p=0.312 
respectively). 
 
All six patients who responded to olaparib showed a decrease in tDV (median: -
41.1%; min, max: -58.8%, -6.3%), but no decrease was observed in any of the 15 non-
responders (median: +20.7%; min, max: +0.0%, +76.9%); this difference between 
responders and non-responders was significant (p=0.001). (Table 3, Appendix figure 
1). Patients who responded to olaparib showed a greater increase in mADC after 12-
weeks of treatment (median: +35.4%; min, max: +1.3%, +59.5%), compared to non-
responders (median: +7.5%; min, max: -9.0%, +32.7%, p=0.14); increases in mADC 
after 12-weeks of treatment were associated with increased odds of response (OR: 
1.08, 95%CI 1.00, 1.15, p=0.037) (Table 4, Appendix figure 2). An example of a 
responding patient is represented in Figure 3. 
The two patients with mixed osteoblastic/osteolytic pattern with predominantly lytic 
bone metastases were non-responders who had +55.5 % and +24.6 % increase of tDV and +3.40 %, + 15.6 % increase of mADC after 12 weeks on treatment respectively. 
The correlation between PSA levels, CTC counts and DWI parameters was also 
explored; baseline PSA levels and CTC counts showed strong and moderate positive 
association with baseline tDV (r=0.64, 95% CI 0.29-0.84; and r=0.59, 95% CI 0.22-
0.82 respectively) and there was a strong positive association between changes in tDV 
and best post-treatment percentage change in PSA and CTC (r=0.63, 95% CI 0.27-
0.83; and r=0.77 95% CI 0.51, 0.90 respectively), indicating that changes in tDV 
correlate with response to therapy.  
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Of the six responding patients, four had a further evaluable WB-MRI at the time of 
radiological and/or PSA progression. In all four cases, we observed a decrease in tDV 
while responding to olaparib, followed by a later increase in tDV at the time of 
radiological and/or PSA progression. Three of these four responding patients also had 
an increase in mADC while responding to treatment, followed by a decrease in 
mADC at the time of radiological and/or PSA progression. The fourth patient 
experienced minimal mADC change at PSA nadir and disease progression. 
(Appendix figures 3 and 4). 
 
Analysis of five target lesions (total volume and central slice) 
With the aim of evaluating more limited radiological analyses, to decrease workload, 
we correlated changes in up to 5 target lesions per patient with treatment response. 
We evaluated 5 target lesions in 19 of the 21 patients (90%); the remaining two 
patients had only one and three evaluable bone lesions respectively. The median sum 
of total volumes corresponding to the target lesions in the population at baseline was 
0.05 L (min, max: 0.01, 0.52 L), and the mADC when delineating total volume of the 
target lesions was 814 x10-6 mm2/s (min, max: 606, 1712x10-6 mm2/s). In patients 
with non-widespread bone disease (N=9) we also assessed the diameter of the target 
lesions in the central slice. When assessing only the central slice of the same target 
lesions, the median of the sum of diameters at baseline was 12.6mm (min, max: 2.8, 
20.2 mm) and the mADC was 835 x10-6 mm2/s (min, max: 554.5, 1263 x10-6 mm/s). 
These parameters grouped by responders and non-responders are summarized in 
Table 2; there were no statistically significant differences between the baseline 
distribution of volume, diameter and mADC (central slice and volume) of the target 
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lesions between the two groups (p=0.876, p=0.143, p=0.312 and, p=0.073 
respectively). 
 
Then, we assessed the same target lesions for each patient in their follow-up WB-MRI 
after 12-weeks of treatment; the percentage change of these parameters after 12-
weeks of treatment is summarized by response status in Table 3, Figure 2. Changes 
in entire lesion volume of the target bone metastases also inversely associated with 
response (OR: 0.89, 95%CI 0.80, 0.99, p=0.037) (Table 4). The mADC change at 12-
weeks, when analyzing the target bone metastases (total volume and central slice), 
also associated with response, although these associations did not reach statistical 
significance (p=0.056 and p=0.082 respectively) (Table 4). Results from the 
multivariate logistic regression analyses showed similar trends (Table 4). 
 
Analysis of the axial skeleton (enclosing normal and abnormal bone marrow) 
The baseline median of the mADC in our population when delineating the entire axial 
skeleton including both normal and abnormal bone marrow was 805 x10-6 mm2/s 
(min, max: 614, 1182 x10-6 mm2/s). mADC at baseline grouped by responders and 
non-responders are summarized in Table 2; there were no statistically significant 
differences between the baseline distributions of mADC between the two groups 
(p=0.94). The percentage change of mADC after 12-weeks of treatment is 
summarized by response status in Table 3, Figure 2. When comparing the mADC of 
the entire axial skeleton (normal and abnormal bone marrow) pre- and-post treatment 
with olaparib, changes in mADC did not associate with response to treatment 
(p=0.518). (Table 4) 
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DISCUSSION 
We hypothesized that changes in volume of bone marrow metastases assessed by 
DWI and changes in mADC are indicators of response of bone metastases to 
treatment in patients with mCRPC. In our study we explored different delineation 
techniques for assessing bone metastases quantitatively and qualitatively with WB-
DWI. One technique included all the areas of DWI signal abnormality in keeping with 
all bone metastases in the axial skeleton (tDV); the other focused on two simpler 
techniques assessing five target lesions, based on the widely used RECIST 1.1 (4), to 
determine whether a simplified approach may be viable in clinical practice. Finally, 
we explored if changes in mADC delineating the entire spine and pelvis (including 
areas of normal and abnormal bone marrow), which may facilitate automated 
delineation, was associated to response. 
 
We have shown that when delineating all the areas of DWI signal abnormality in 
keeping with bone metastases in the axial skeleton (from C4 to mid-thigh), the 
changes detected in tDV and mADC after 12-weeks on treatment allow the 
identification of responders in mCRPC with bone metastases. Decreases in tDV 
correlated with decreases in PSA levels and CTC count falls, and also with overall 
response as defined as a composite endpoint in the TOPARP-A clinical trial (23). 
Consistent with the fact that tumor cell death results in increased water diffusivity 
manifested as higher ADC values, patients who responded to olaparib also showed a 
greater increase in mADC compared to non-responders. In our population, the results 
of simpler ways of assessing bone metastases on WB-DWI in 5 selected target lesions 
(total volume or central slice) support further evaluation of this faster and more 
practical approach in future studies; as decreases in volume and diameter of the five 
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target lesions after 12-weeks on treatment associated with response. There was also a 
trend of significance when associating mADC increases of the target lesions at 12-
weeks and response. Therefore, overall, these data indicate that WB-DWI may have a 
role in bone metastases response assessment in mCRPC, without need of ionizing 
radiation or intravenous contrast, potentially allowing the detection of differential 
responses in visceral or nodal metastases and bone metastases. Clinical qualification of WB-DWI as response biomarker in bone metastases would improve assessment of response to treatment in mCRPC, allowing for optimization of patients care, treatment decision and drug development in this common disease. 
Conversely, when delineating spine and pelvis, including all areas of normal and 
abnormal bone marrow, increases in mADC after 12-weeks on treatment did not 
associate to response; probably due to the fact that changes in mADC in bone 
metastases are diluted by the absence of changes in mADC in normal bone marrow.  
 
We acknowledge the potential limitations of our study; firstly, due to the small size of 
this pilot study, only limited exploration of the impact of adjustment for other clinical 
factors on the association of changes in tDV and mADC is possible. Analyzing larger 
populations in multi-center studies is now needed for future validation of these results 
and to allow multivariate analyses. Secondly, all our patients were treated with one 
drug, the PARP inhibitor olaparib; however, previous studies have identified similar 
changes in DWI in bone metastases responding to hormonal therapy and cytotoxics 
(18-21). Prospective studies to replicate our results with established treatments for 
mCRPC are now needed. Thirdly, it should be noted that the ROI delineation depends 
on the quality of the acquired DWI data, the semi-automatic segmentation tool and 
radiologist expertise. Prior studies reported high intra-reader reproducibility of DWI 
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analysis using similar bone metastases delineation methodology (17, 25), although 
this needs to be validated in larger, properly powered studies. Finally, we 
acknowledge that the majority of our population had sclerotic bone metastases, only 2 patients had predominantly lytic bone metastases; therefore, it was not feasible to perform comparison between the sclerotic vs lytic nature of the bone metastases. Despite these limitations, our study represents the largest prospective 
series to date in a trial of a novel therapeutic assessing response to drug treatment in 
bone metastases in patients with mCRPC using WB-DWI. The data presented here 
highlight the potential of DWI for bone metastases response assessment and warrants 
further evaluation of WB-DWI in this disease. 
 
In conclusion, we have shown that assessment of bone metastases with WB-DWI 
during anticancer treatment is feasible, with changes in bone metastases volume and 
mADC being indicators of response to treatment in mCRPC in our pilot study. 
Moreover, the more efficient study of five target lesions has substantial practical merit 
for disease evaluation, which can be more easily adopted into clinical practice. These 
results support further evaluation of DWI as a response biomarker in prospective 
mCRPC patient cohorts, ideally embedded into clinical trials (26).  
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Table 1. Baseline characteristics and prior treatments of the overall population 
included in the whole body MRI study (N=21). 
Q1: 1st quartile, Q3: 3rd quartile 
Clinical characteristics Median (Q1, Q3) Min, max 
Hemoglobin (g/dL) 10.9 (10.2, 11.5) 9.2, 14.2 
Prostate Specific Antigen 
(ng/mL) 411 (146, 806) 19, 2949 
Alkaline Phosphatase (IU/L) 147 (86, 363) 54, 2652 
Lactate Dehydrogenase (IU/L) 234 (176, 318) 109, 862 
Albumin (g/dL) 3.5 (3.1, 3.7) 2.7, 4.0 
Circulating Tumor Cell count 
(number/7.5ml) 46 (8, 102) 3, 187 
Prior treatments No. % 
Docetaxel 21 100.0 
Cabazitaxel 11 52.4 
Abiraterone acetate 19 90.5 
Enzalutamide 4 19.0 
Radium-223 1 4.8 
Bisphosphonates 4 19.0 
Palliative radiotherapy to bone 6 28.6 
Sites of metastatic disease No. % 
Bone  21 100 
Nodal 12 57.1 
Liver 6 28.6 
Lung  5 23.8 
Bone only 7 33.3 
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Table 2. Baseline circulating tumor cells (CTC) count, prostate specific antigen 
(PSA) and characteristics of the bone metastases assessed by whole body diffusion 
weighted imaging (WB-DWI) with the different delineation techniques in responders 
and non-responder patients.  
Q1: 1st quartile, Q3: 3rd quartile 
  
Responders Non-responders Mann-
Whitney 
p-value N Median (Q1, Q3 ) Min, max N Median (Q1, Q3) Min, max 
Clinical characteristics 
CTC 
(number/7.5ml) 6 63 (8, 102) 3, 105 15 46 (8, 104) 6, 187 0.845 
PSA (ng/ml) 6 868 (34, 1847) 28, 2949 15 381 (146, 456) 19, 1505 0.350 
Axial skeleton DWI signal abnormality 
Volume (L) 6 0.83 (0.17, 1.01) 0.16, 1.31 15 0.44 (0.16, 0.79) 0.01, 1.07 0.243 
Median ADC          
(x10-6 mm2/s) 
6 847 (775, 921) 693, 1121 15 748 (726, 915) 684, 1023 0.312 
Up to 5 target lesions 
Volume (L) 6 0.05 (0.04, 0.06) 0.04, 0.09 15 0.05 (0.02, 0.12) 0.01, 0.52 0.876 
Median ADC          
(x10-6 mm2/s) 
6 859 (814, 900) 606, 1712 15 737 (695, 865) 624, 1017 0.312 
Central slice 5 target lesions 
Diameter (mm) 2 15.3 (14.3, 16.3) 14.3, 16.3 7 11.6 (7.5, 13.1) 2.8, 20.2 0.143 
Median ADC          
(x10-6 mm2/s) 
6 941 (867, 1002) 555, 1263 15 743 (673, 852) 575, 1083 0.073 
Entire axial skeleton 
Median ADC          
(x10-6 mm2/s) 
6 808 (650, 1093) 614, 1182 15 805 (751, 1002) 722, 1039 0.938 
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Table 3. Percentage change after 12 weeks on treatment of the circulating tumor cells 
(CTC) counts, prostate specific antigen (PSA) and the parameters derived from the 
whole body diffusion weighted imaging (WB-DWI) analysis with the different 
delineation techniques in responders and non-responders patients. 
 
% change after 12 
weeks   
Responders  Non-responders Mann-
Whitney 
p-value N 
Median  
(Q1, Q3) Min, max N 
Median  
(Q1, Q3 ) Min, max 
Clinical characteristics 
CTC 
(number/7.5ml) 6 
-96.0  
(-100, -82.9) -100, -60.5 15 
-2.9  
(-37.5, 75.0) -73.8, 312.5 NA* 
PSA (ng/ml) 6 
-68.6  
(-80.1, -37.5) -94.6, -29.3 15 
89.9  
(36.0, 239.0) -14.4, 525.6 NA* 
Axial skeleton DWI signal abnormality 
Volume (L) 6 
-41.1  
(-52.9, -28.7) -58.8, -6.3 15 
20.7  
(3.2, 53.0) 0.0, 76.9 0.001 
Median ADC          
(x10-6 mm2/s) 
6 35.4  (3.8, 44.1) 1.3, 59.5 15 
7.5  
(3.7, 15.6) -9.0, 32.7 0.139 
Up to 5 target lesions 
Volume (L) 6 
-25.5  
(-57.0, -18.2) -78.7, 4.54 15 
14.6  
(0.0, 47.5) -20.2, 76.9 0.002 
Median ADC          
(x10-6 mm2/s) 
6 26.3  (11.4, 47.4) 4.8, 102.9 15 
7.4  
(-2.3, 12.9) -10.8, 25.6 0.024 
Central slice 5 target lesions 
Diameter (mm) 2 
-59.2  
(-88.3, -30.1) -88.3, -30.1 7 
3.8  
(1.6, 41.4) 0.0, 69.9 0.040 
Median ADC          
(x10-6 mm2/s) 
6 27.4  (14.0, 47.0) 12.8, 52.3 15 
10.0  
(3.2, 17.2) -12.7, 63.1 0.018 
Entire axial skeleton 
Median ADC          
(x10-6 mm2/s) 
6 7.4  (-0.8, 26.0) -16.6, 29.0 15 
5.6  
(3.4, 12.5) -21.6, 16.7 0.876 
* Changes in CTC and PSA were used to define response/non-response therefore formal comparisons have 
not been made. 
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Table 4. Associations of total diffusion volume (tDV), volume and diameter of the 
target lesions and median ADC (mADC) changes between baseline and 12 weeks 
with binary response to treatment were assessed using logistic regression. 
OR: Odds ratio 
 N 
Univariate Multivariate† 
OR (95% CI) p-value OR (95% CI) p-value 
 Axial skeleton DWI signal abnormality 
Volume (L) 21 Not-calculable*  Not-calculable*  
Median ADC          
(x10-6 mm2/s) 21 1.08 (1.00, 1.15) 0.037 1.16 (1.01, 1.33) 0.04 
  Up to 5 target lesions 
Volume (L) 21 0.89 (0.80, 0.99) 0.037 0.53 (0.09, 3.15) 0.48 
Median ADC          
(x10-6 mm2/s) 21 1.10 (1.00, 1.22) 0.056 1.13 (0.95, 1.33) 0.17 
  Central slice 5 target lesions 
Median ADC          
(x10-6 mm2/s) 21 1.05 (0.99, 1.11) 0.082 1.07 (0.99, 1.15) 0.07 
  Entire axial skeleton 
Median ADC          
(x10-6 mm2/s) 21 1.03 (0.94, 1.12) 0.518 1.03 (0.93, 1.15) 0.56 
*Unable to fit model as change in volume <0% predicts data perfectly 
† Adjusting for baseline PSA, LDH and ALP 
    
 
 
 
 
 
 
 
Figure 1. Images show the different delineation techniques in two-dimensional 
coronal or axial views for illustrative purpose. Areas of signal abnormality 
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corresponding to high signal intensity on DWI (b = 900 mm/s2) and low signal 
intensity on T1-weighted image, in keeping with bone metastases observed between 
C4 and the mid-thigh were delineated on DWI (b= 900mm/s2) (a). In order to explore 
a more limited approach, total volume (b) and central axial slice (c) of up to 5 target 
lesions were delineated on DWI (b= 900mm/s2). (d) Finally, the entire axial skeleton 
including areas of normal and abnormal signal abnormality was delineated.  
 
Figure 2. Consort diagram of study selection process. 
 
Figure 3. Images of mCRPC in a 70-year-old man responding to olaparib showing 
reduction in the b900 DWI signal abnormality extent on maximum intensity 
projection images (b=900 s/mm2) at baseline (a) and after 12 weeks of treatment (b). 
The histogram (c) depicts the ADC values of the tDV at baseline and after 12 weeks 
on treatment, showing an increase in the mADC. 
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Appendix table 1. Imaging parameters for whole body MRI. 
 
PARAMETER T1 weighted imaging DWI 
MRI platform 1.5-T scanner (Avanto, Siemens Healthcare) 
Type of pulse sequence 
Spoiled gradient echo 
(FLASH) 
Single-shot twice-refocused 
echo-planar imaging 
Respiration Breath-hold Free-breathing 
Type of acquisition 2D 2D 
Field of view (mm) 380-420 380-420 
Repetition time (ms) 380 14000 
Echo time (ms) 5 68 
Inversion time (ms) NA 180 
Flip angle 70 90 
Fat suppression NA STIR 
Receiver bandwidth (Hz/pixel) 331 1800 
Number of signal average 1 4 
Section thickness (mm) 5 5 
b factors (s/mm2) NA 50 and 900 
Number stations 4 (50 slices each) 4 (50 slices each) 
Note: A 1.5-T MR scanner (Avanto, Siemens Healthcare) was used for imaging. 
DWI= Diffusion Weighted Imaging, FLASH = fast low-angle shot, NA = not 
applicable, STIR = short inversion time inversion recovery, 2D = two-dimensional.  
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Appendix figure 1. Box-plots of  (a) percentage volume/diameter change of bone 
metastases, delineated on axial DWb900, and (b) median apparent diffusion 
coefficient (mADC) at 12 weeks assessed by different delineation techniques.  
* Logistic regression (p<0.05) 
 
Appendix figure 2. Scatter plot of total diffusion volume (tDV) and median apparent 
diffusion coefficient (mADC) change when delineating axial skeleton diffusion signal 
abnormality in responders (green circles) and non-responders (red crosses). 
 
Appendix figure 3. Scatter plots of percentage change of total diffusion volume 
(tDV) (triangles) and median apparent diffusion coefficient (mADC) (circles) at 
response and disease progression in those 4 responder patients with evaluable whole 
body MRI. 
 
Appendix figure 4. Images in a 70-year-old mCRPC man on olaparib. Initially, the 
12 weeks axial MRI images showed a reduction of the DWI (b = 900 mm/s2) signal 
abnormality extent in the lumbar vertebrae bone metastases and an increase in mADC 
values compared to baseline; subsequently a follow-up MRI showed an increase of 
signal abnormality extent on DWI (b = 900 mm/s2) and a decrease in the mADC 
values in the same bone metastases, in keeping with disease progression. The 
histogram depicts the ADC values of the tDV at baseline, after 12 weeks on treatment 
and at progression. 
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Figure 1a. Images show the different delineation techniques in two-dimensional coronal or axial views for 
illustrative purpose. Areas of signal abnormality corresponding to high signal intensity on DWI (b = 900 
mm/s2) and low signal intensity on T1-weighted image, in keeping with bone metastases observed between 
C4 and the mid-thigh were delineated on DWI (b= 900mm/s2) (a). In order to explore a more limited 
approach, total volume (b) and central axial slice (c) of up to 5 target lesions were delineated on DWI (b= 
900mm/s2). (d) Finally, the entire axial skeleton including areas of normal and abnormal signal abnormality 
was delineated.  
Figure 1  
32x50mm (300 x 300 DPI)  
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Figure 1b. Images show the different delineation techniques in two-dimensional coronal or axial views for 
illustrative purpose. Areas of signal abnormality corresponding to high signal intensity on DWI (b = 900 
mm/s2) and low signal intensity on T1-weighted image, in keeping with bone metastases observed between 
C4 and the mid-thigh were delineated on DWI (b= 900mm/s2) (a). In order to explore a more limited 
approach, total volume (b) and central axial slice (c) of up to 5 target lesions were delineated on DWI (b= 
900mm/s2). (d) Finally, the entire axial skeleton including areas of normal and abnormal signal abnormality 
was delineated.  
Figure 1  
32x50mm (300 x 300 DPI)  
 
 
Page 33 of 48
Prudential Tower, 800 Boylston Street, 15th Floor, Boston, MA 02199
RADIOLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
Figure 1c. Images show the different delineation techniques in two-dimensional coronal or axial views for 
illustrative purpose. Areas of signal abnormality corresponding to high signal intensity on DWI (b = 900 
mm/s2) and low signal intensity on T1-weighted image, in keeping with bone metastases observed between 
C4 and the mid-thigh were delineated on DWI (b= 900mm/s2) (a). In order to explore a more limited 
approach, total volume (b) and central axial slice (c) of up to 5 target lesions were delineated on DWI (b= 
900mm/s2). (d) Finally, the entire axial skeleton including areas of normal and abnormal signal abnormality 
was delineated.  
Figure 1  
32x22mm (300 x 300 DPI)  
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Figure 1d. Images show the different delineation techniques in two-dimensional coronal or axial views for 
illustrative purpose. Areas of signal abnormality corresponding to high signal intensity on DWI (b = 900 
mm/s2) and low signal intensity on T1-weighted image, in keeping with bone metastases observed between 
C4 and the mid-thigh were delineated on DWI (b= 900mm/s2) (a). In order to explore a more limited 
approach, total volume (b) and central axial slice (c) of up to 5 target lesions were delineated on DWI (b= 
900mm/s2). (d) Finally, the entire axial skeleton including areas of normal and abnormal signal abnormality 
was delineated.  
Figure 1  
32x50mm (300 x 300 DPI)  
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Figure 2. Consort diaphragm of study selection process.  
Figure 2  
70x43mm (300 x 300 DPI)  
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Figure 3a. Images of mCRPC in a 70-year-old man responding to olaparib showing reduction in the b900 
DWI signal abnormality extent on maximum intensity projection images (b=900 s/mm2) at baseline (a) and 
after 12 weeks of treatment (b). The histogram (c) depicts the ADC values of the tDV at baseline and after 
12 weeks on treatment, showing an increase in the mADC.  
Figure 3  
35x50mm (300 x 300 DPI)  
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Figure 3b. Images of mCRPC in a 70-year-old man responding to olaparib showing reduction in the b900 
DWI signal abnormality extent on maximum intensity projection images (b=900 s/mm2) at baseline (a) and 
after 12 weeks of treatment (b). The histogram (c) depicts the ADC values of the tDV at baseline and after 
12 weeks on treatment, showing an increase in the mADC.  
Figure 3  
35x50mm (300 x 300 DPI)  
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Figure 3c. Images of mCRPC in a 70-year-old man responding to olaparib showing reduction in the b900 
DWI signal abnormality extent on maximum intensity projection images (b=900 s/mm2) at baseline (a) and 
after 12 weeks of treatment (b). The histogram (c) depicts the ADC values of the tDV at baseline and after 
12 weeks on treatment, showing an increase in the mADC.  
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Appendix figure 1a. Box-plots of  (a) percentage volume/diameter change of bone metastases, delineated 
on axial DWb900, and (b) median apparent diffusion coefficient (mADC) at 12 weeks assessed by different 
delineation techniques.  
* Logistic regression (p<0.05)  
 
Appendix figure 1  
39x29mm (300 x 300 DPI)  
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Appendix figure 1b. Box-plots of  (a) percentage volume/diameter change of bone metastases, delineated 
on axial DWb900, and (b) median apparent diffusion coefficient (mADC) at 12 weeks assessed by different 
delineation techniques.  
* Logistic regression (p<0.05)  
 
Appendix figure 1  
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Appendix figure 2. Scatter plot of total diffusion volume (tDV) and median apparent diffusion coefficient 
(mADC) change when delineating axial skeleton diffusion signal abnormality in responders (green circles) 
and non-responders (red crosses).  
Appendix figure 2  
39x29mm (300 x 300 DPI)  
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Appendix figure 3. Scatter plots of percentage change of total diffusion volume (tDV) (triangles) and median 
apparent diffusion coefficient (mADC) (circles) at response and disease progression in those 4 responder 
patients with evaluable whole body MRI.  
Appendix figure 3  
39x29mm (300 x 300 DPI)  
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Appendix figure 4. Images in a 70-year-old mCRPC man on olaparib. Initially, the 12 weeks axial MRI 
images showed a reduction of the DWI (b = 900 mm/s2) signal abnormality extent in the lumbar vertebrae 
bone metastases and an increase in mADC values compared to baseline; subsequently a follow-up MRI 
showed an increase of signal abnormality extent on DWI (b = 900 mm/s2) and a decrease in the mADC 
values in the same bone metastases, in keeping with disease progression. The histogram depicts the ADC 
values of the tDV at baseline, after 12 weeks on treatment and at progression.  
Appendix figure 4  
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 1 
STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 Item 
No 
Recommendation  (N/A) 
Title and abstract    
 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
 
page 5 line 21 
(b) Provide in the abstract an informative and balanced summary of what was 
done and what was found 
 
page 5 
lines 27-60 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
 
page 7 
lines 22-44 
Objectives 3 State specific objectives, including any prespecified hypotheses  
page 8 
lines 6-26 
Methods  
Study design 4 Present key elements of study design early in the paper  
page 9  
lines 6-46 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
 
page 8 
lines 38-48 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods 
of case ascertainment and control selection. Give the rationale for the choice 
of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and 
methods of selection of participants 
 
page 9 line 51 
to 
page 10  
line 14 
(b) Cohort study—For matched studies, give matching criteria and number of 
exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the 
number of controls per case 
N/A 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable 
 
page 9 
lines 36-46 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group 
 
page 10 line 
52 to page 12 
line 12 
Bias 9 Describe any efforts to address potential sources of bias  
page 12 lines 
30-34 
Study size 10 Explain how the study size was arrived at  
page 9 line 
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 2 
51 to page 10 
line 14 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
 
page 12 lines 
20-30 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
 
page 12 lines 
20-50 
(b) Describe any methods used to examine subgroups and interactions N/A 
(c) Explain how missing data were addressed N/A 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls 
was addressed 
Cross-sectional study—If applicable, describe analytical methods taking 
account of sampling strategy 
N/A 
(e) Describe any sensitivity analyses N/A 
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 3 
 
Results   (N/A) 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, 
and analysed 
 
page 9 
line 51 to 
page 10 
line 14 
(b) Give reasons for non-participation at each stage  
page 9 
line 51 to 
page 10 
line 14 
(c) Consider use of a flow diagram  
page 13 
line 26 
Descriptive 
data 
14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
 
page 13 
line 6-28 
(b) Indicate number of participants with missing data for each variable of interest  
page 13 
line 14-22 
(c) Cohort study—Summarise follow-up time (eg, average and total amount)  
page 9 
line 30-36 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time  
page 9 
line 51 to 
page 10 
line 14 
Case-control study—Report numbers in each exposure category, or summary measures of 
exposure 
N/A 
Cross-sectional study—Report numbers of outcome events or summary measures N/A 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
 
page 12 
line 30-48 
(b) Report category boundaries when continuous variables were categorized N/A 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
N/A 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity 
analyses 
 
page 9 
line 30-34 
Discussion  
Key results 18 Summarise key results with reference to study objectives  
page 17 
line 48 to 
page 18 
line 32 
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 4 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
 
page 19 
line 12-40 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
 
page 19 
line 40-50 
Generalisability 21 Discuss the generalisability (external validity) of the study results  
page 20 
line 6-18 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
 
page 9 
line 18-24 
and 
page 21 
line 7-39 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at www.strobe-statement.org. 
 
*N/A%stands%for%not%applicable%and%may%be%a%reasonable%choice%depending%on%the%type%of%study%
performed%
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